Lipella Pharmaceuticals has concluded subject enrolment in its Phase IIa trial of LP-310, aimed at treating oral lichen planus (OLP).

AstraZeneca recently announced positive toplined interim results from SERENA-6, a randomised, multicentre, double-blind Phase ...

Apnimed has dosed the first subject in the Phase IIA RESTEADY trial of SASS-001, an oral drug combo for sleep apnoea with a ...

The UK Government has announced a £600m ($764m) funding pot to create a new Health Data Research Service, reducing red tape ...

US President Donald Trump told reporters last week that pharma tariffs are coming “sometime in the near future”.

The FDA has granted clearance to CureVac's IND for the open-label Phase I trial of CVHNLC in individuals with sqNSCLC.

Blarcamesine is a sigma 1 receptor agonist which targets Alzheimer's pathology upstream of amyloid and tau pathology.

Rhythm's Imcivree has shown benefit in a Phase III trial in patients with acquired hypothalamic obesity, leading to 19.8% ...

If approved, LMTX has the potential to become the first orally available disease-modifying therapy (DMT) in the UK.

Sonnet BioTherapeutics has reported positive safety outcomes from a trial of SON-1010 with atezolizumab for solid tumours or ...

Johnson & Johnson has reported positive results from a Phase IIIb trial of Tremfya (guselkumab) for active psoriatic ...

Sarepta and Roche announced a 16-year-old US patient dosed with Elevidys died of acute liver failure in March 2025.